16975-39-6

Usage

Uses

Used in Pharmaceutical Research:
2-(benzylamino)-3-methylbutanoic acid is used as a potential inhibitor of the enzyme histone deacetylase for its role in regulating gene expression and cell growth. This application is significant in the development of treatments for various diseases, including cancer.
Used in Cancer Therapy:
In the field of oncology, 2-(benzylamino)-3-methylbutanoic acid is being explored for its potential anti-cancer properties. Its ability to target histone deacetylase may contribute to the modulation of cancer cell behavior, offering a new avenue for therapeutic intervention.
Used in Medicinal Chemistry:
2-(benzylamino)-3-methylbutanoic acid serves as a building block in the synthesis of various compounds for medicinal applications. Its unique structure allows for the creation of new molecules with potential therapeutic effects, expanding the scope of available pharmaceuticals.
Used in Chemical Synthesis:
Beyond medicinal applications, 2-(benzylamino)-3-methylbutanoic acid is utilized as a component in the synthesis of compounds for a range of chemical applications. Its versatility in chemical reactions makes it a valuable precursor in the development of new chemical entities for various industries.

Upstream product

• 100-52-7 benzaldehyde 
• 516-06-3 D,L-valine 
• 105623-17-4 N-(2-methylpropylidene)benzylamine-N-oxide 
• 124-38-9 carbon dioxide 
• 22483-21-2 isobutylidenebenzylamine 

Downstream Products

• 3103-29-5 N-Acetoacetyl-N-benzyl-valin 
• 15363-84-5 (S)-2-(benzylamino)-3-methylbutanoic acid 
• 1449563-40-9 diethyl [1-(dibenzylamino)-2-methylpropyl]phosphonate 
• 28897-81-6 2-phenyl-4-iso-propyl-4H-oxazolin-5-one 
• 1314238-70-4 [1-[benzyl(4-cyanobenzyl)amino]-2-methylpropyl]phosphonic acid diethyl ester 
• 98575-68-9 (R)-N-benzylvaline 
• 105623-17-4 (Z)-N-(2-methylpropylidene)benzylamine N-oxide 

Relevant academic research and scientific papers

Discovery of Novel N-(4-Hydroxybenzyl)valine Hemoglobin Adducts in Human Blood

Humans are exposed to a wide range of electrophilic compounds present in our diet and environment or formed endogenously as part of normal physiological processes. These electrophiles can modify nucleophilic sites of proteins and DNA to form covalent addu

ANTIVIRAL COMPOUNDS

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

Synthesis of α-amino acids through samarium(II) iodide promoted reductive coupling of nitrones with CO2

Several N-benzylnitrones reacted with carbon dioxide in the presence of samarium(II) iodide leading to α-amino acids as the products of reductive C-C coupling. The best selectivities were observed at a carbon dioxide pressure of 50 bar at ambient temperature. The influences of different functional groups in the nitrone backbone and of the coordinating additives to samarium(II) iodide on the product distribution were investigated. The racemic α-amino acids were obtained in up to 70% yield based on HPLC data. A novel approach to the synthesis ofα-amino acids is disclosed, involvingC-carboxylation of nitrones by gaseous CO2 under reductive coupling reaction conditions (SmI2, 0.1 M in THF) at ambient temperature and 50 bar of CO 2 pressure. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Resolution of racemic N-benzyl α-amino acids by liquid-liquid extraction: A practical method using a lipophilic chiral cobalt(III) salen complex and mechanistic studies

The efficient resolution of racemic N-benzyl α-amino acids (N-Bn-AA) has been achieved by a liquid-liquid extraction process using the lipophilic chiral salen-cobalt(III) complex [CoIII(3)(OAc)]. As a result of the resolution by extraction, one enantiomer (S) of the N-benzyl α-amino acid predominated in the aqueous phase, while the other enantiomer (R) was driven into the organic phase by complexation to cobalt. The complexed amino acid (R) was then quantitatively released by a reductive (CoIII→Co II) counter-extraction with aqueous sodium dithionite or L-ascorbic acid in methanol. The reductive cleavage allowed to recover the [Co II(3)] complex in good yield, which could be easily re-oxidized to [CoIII(3)(OAc)] with air/AcOH and reused with essentially no loss of reactivity and selectivity. Investigation on the nitrogen substitution indicates that the presence of a single benzyl group on the amino acid nitrogen is important to obtain high enantioselectivity in the extraction process. The kinetic vs. thermodynamic nature of the resolution process was also investigated with an enantiomeric exchange experiment, which shows that the liquid-liquid extraction with [CoIII(3)-(OAc)] is an equilibrium process operating under thermodynamic control. In the absence of a suitable crystal structure of the [CoIII(3)(N-Bn-AA)] complexes, computational and spectroscopic studies were used to investigate how the N-benzyl α-amino acids are accommodated in the "binding pocket" of the chiral cobalt complex. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

A practical approach to the resolution of racemic N-benzyl α-amino acids by liquid-liquid extraction with a lipophilic chiral salen-cobalt(III) complex

(Chemical Equation Presented) Liquidating the assets: Coordination of one enantiomer from a racemic mixture of N-benzyl α-amino acids (N-Bn-AA) to the lipophilic chiral [CoIII(salen)(OAc)] complex results in its extraction into the organic phas